Compare Enveric Biosciences Inc (ENVB) vs Lam Research Corporation (LRCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Lam Research Corporation — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Lam Research Corporation trades at $326.81 (market cap $401.19B). The key difference: Lam Research Corporation is far larger — about 58998.5× Enveric Biosciences Inc's market cap, and Lam Research Corporation pays a 0.41% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Lam Research Corporation for 60 Days on average.
| ENVB | LRCX | |
|---|---|---|
Market Cap | $6.80M | $401.19B |
Volume | 64,867 | 8,960,892 |
Sector | Health | Technology |
52-Week High | $10.80 | $433.33 |
52-Week Low | $1.27 | $131.37 |
Typical Hold Time | 14 Days | 60 Days |
Enterprise Value | -$1.49M | $399.35B |
Dividend Yield | — | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Lam Research (LRCX) trades at $329.51, down 1.31% on the day, amid a bullish technical setup with strong support at $326 and resistance at $332. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.82 exceeding the $1.69 estimate. Revenue growth accelerated to $18.44B in 2025, driving a net income margin of 31.27%. Analyst sentiment remains overwhelmingly positive, with 78% recommending Buy and a consensus price target of $375.68, suggesting significant upside potential from current levels.
LRCX is well-positioned to capitalize on AI-driven demand for semiconductor equipment, supported by expanding margins and strong cash flow. However, elevated valuation multiples (P/E of 57.21) and exposure to cyclical chip industry downturns pose risks. The stock offers growth appeal for investors bullish on sustained tech capex, but requires monitoring of competitive pressures and macroeconomic headwinds that could impact equipment spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →
